ReviewFrontiers in immunology2025
Fibroblasts as a ruler of the immune microenvironment: measurement and modulation in tissue homeostasis and disease.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- cGAS-STING signaling in aging and age-related diseases: therapeutic promise and precaution.Archives of pharmacal research · 2026Review
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibroblasts, once considered merely passive structural components of tissues, are now recognized as dynamic regulators of the immune microenvironment. Recent advances in single-cell and spatial multi-omics have revealed their profound heterogeneity, spatial organization, and functional plasticity, positioning them as a 'ruler' that measures, defines, and shapes local immune responses. In both homeostasis and disease contexts-such as cancer, autoimmune disorders, and fibrosis-distinct fibroblast subpopulations exhibit specialized roles: some drive immunosuppression via PD-L1 expression, TGF-β secretion, or metabolic reprogramming; others promote inflammation or fibrosis through cytokine and chemokine secretion; while a subset supports immune resolution and tissue repair. Spatially, fibroblasts organize immune territories by forming physical and chemical barriers, orchestrating tertiary lymphoid structures, and partitioning inflammatory zones. Their bidirectional crosstalk with immune cells-including T cells, macrophages, and B cells-further fine-tunes immune activation or suppression. The dysregulation of fibroblast subsets is a hallmark of disease progression and therapy resistance. Emerging therapeutic strategies aim to 'recalibrate' this dysfunctional ruler through targeted depletion, phenotypic reprogramming, or disruption of pathogenic signaling. Integrating fibroblast-centric metrics into clinical practice may enable precise assessment of the immune microenvironment and personalized interventions, heralding a new era in immunotherapy and fibrotic disease management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.